A Study to Determine the Abuse Potential of Tozadenant Relative to D-Amphetamine and Placebo When Administered Orally in Healthy, Non-Dependent, Recreational Polydrug Users
A Randomized, Double-Blind, 6-Way Crossover Study to Determine the Abuse Potential of Tozadenant Relative to D-Amphetamine and Placebo When Administered Orally in Healthy, Non-Dependent, Recreational Polydrug Users With Stimulant Experience, Under Fed Conditions
Sponsor: Acorda Therapeutics
Terminated
New Safety Information
A PHASE1 clinical study on Abuse Potential, this trial is terminated or withdrawn. The trial is conducted by Acorda Therapeutics and has accumulated 8 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Sep 2018 — Jan 2021 [monthly]
Terminated PHASE1
-
Jun 2018 — Sep 2018 [monthly]
Terminated PHASE1
▶ Show 3 earlier versions
-
Jan 2018 — Jun 2018 [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
Oct 2017 — Jan 2018 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Aug 2017 — Oct 2017 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Acorda Therapeutics
- Biotie Therapies Inc.
For direct contact, visit the study record on ClinicalTrials.gov .